Times of IndiaAmrita's heart goes out for 26/11 victimsTimes of IndiaI would like to make a big request to the legal authorities of India to revise their laws to tackle such perpetrators of peace in a better and quicker way. I'd also like to re…
Moneycontrol.comIndia vs England 2nd Test: Battles to look out for…Indian Sports newsIndia vs England 2nd Test: Battles to look out for… The focus has now shifted from Ahmedabad to Mumbai, the heart of Indian cricket and the venue for the second Te…
(MENAFN – ProactiveInvestors – Australia) Living Cell Technologies (ASX: LCT; OTCQX: LVCLY) has begun patient recruitment in Argentina for a phase IIb trial of DIABECELL® to treat type-1 …
Times of IndiaNutrition tips for marathon runnersTimes of IndiaThe aim of carbohydrate loading is to top up liver and muscle glycogen stores to delay fatigue, thereby enabling the body to maintain high intensity activity during longer runs. Therefore, …
Nita French said Thanksgiving is a good time for families to talk about organ donation.
India TodayLosing job causes heart attack?India TodayResearchers found that being out of work was associated with an increased risk of heart attack, and this risk rose each extra time someone was fired or made redundant. Dr Matthew Dupre and colleagues…
Winter smog is not an act of God (Comment)Newstrack IndiaThis year's smog has been particularly severe because overall pollution levels in the city have gone up manifold ? the tiny particle less than 10 micron size (PM10) that goes deep inside the …
Gwynne Dyer: Shutting down nuclear power stations is madnessStraight.comOver two-thirds of them are being built in the BRICs (Brazil, Russia, India and China), where economies are growing fast and governments are increasingly concerned about both pollu…
22 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has begun patient recruitment in Argentina for a Phase IIb trial of DIABECELL®.
22 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced the results of an interim analysis of its Argentinian Phase I/IIa clinical trial for DIABECELL®, a breakthrough…